Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies

Dempsey, Naomi; Rosenthal, Amanda; Dabas, Nitika; Kropotova, Yana; Lippman, Marc E.; Bishopric, Nanette H.

doi:10.1007/s10549-021-06280-x

Cited by 89 publications

(62 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4, Table 2). These affinities were measured with purified proteins and calculated using a 1:1 stoichiometry, but the physiologically relevant interaction involves ~10 5 FcγRIIIa receptors expressed on an NK cell (45). FcγRIIIa signalling is triggered after binding antibody Fc domains that are clustered due to their Fab arms recognizing multiple adjacent ligand molecules on the target cell surface (46).…”

Section: Discussionmentioning

confidence: 99%

“…During treatment of Her2+ breast cancer with the anti-Her2 Trastuzumab, clinical results have shown a clear correlation between treatment and impairment of the left ventricular ejection fraction (3,4), resulting in cardiac dysfunction. These complications can lead to a reduced tolerance for and even discontinuation of therapy (5). In addition to expressing tumor-associated antigens, tumors also alter their local tissue environments, which presents opportunities for tumor targeting via characteristics orthogonal to antigen specificity.…”

Section: Introductionmentioning

confidence: 99%

“…During treatment of Her2+ breast cancer with the anti-Her2 trastuzumab, clinical results have shown a clear correlation between treatment and impairment of the left ventricular ejection fraction ( 3 , 4 ), resulting in cardiac dysfunction. These complications can lead to a reduced tolerance for and even discontinuation of therapy ( 5 ).…”

mentioning

confidence: 99%

See 2 more Smart Citations

An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH

Liu

Lee

Nguyen

et al. 2022

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH

Liu

Lee

Nguyen

et al. 2022

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Cardiovascular (CV) adverse effects have been reported with HER2-, VEGF-, and EGFR-targeted antibodies. All 5 anti-HER2 antibodies on the US market are associated with cardiotoxicity, and the greatest CV risk is with trastuzumab [ 59 ]. Risk factors include advanced age, comorbid cardiac disease, and treatment with anthracyclines.…”

Section: Targeted Antibodiesmentioning

confidence: 99%

Cancer Immunotherapies: What the Perioperative Physician Needs to Know

et al. 2022

View full text Add to dashboard Cite

Purpose of ReviewFor patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. Recent Findings The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immunerelated adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. Summary Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients.

show abstract

“…Pertuzumab is a recombinant humanized mAb binding to the extracellular dimerization domain II of HER2 to prevent the ligandinduced HER2 heterodimer formation and reduce the survival of tumor (Barthelemy et al, 2014). However, mAb-based immunotherapy has raised new questions about assessment of drug toxicity, the economics of cancer therapy, and resistance to treatments (Kristeleit et al, 2016;Dempsey et al, 2021). Hitherto, HER2-targeted medications have not been applied clinically to treat OSCC, so that there is an urgent need to develop HER2based alternative and safe therapies.…”

Section: Introductionmentioning

confidence: 99%

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma

Liu

He²,

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Natural autoantibodies play a crucial role in destruction of malignant tumors due to immune surveillance function. Epidermal growth factor receptor 2 (HER2) has been found to be highly expressed in a variety of epithelial tumors including oral squamous cell carcinoma (OSCC). The present study was thus undertaken to investigate the effect of anti-HER2 natural autoantibodies on OSCC. Compared with cancer-adjacent tissues, cancer tissues from OSCC patients exhibited higher HER2 expression especially in those with middle & advanced stage OSCC. Plasma anti-HER2 IgG levels examined with an enzyme-linked immunosorbent assay (ELISA) developed in-house showed differences between control subjects, individuals with oral benign tumor and patients with OSCC. In addition, anti-HER2 IgG-abundant plasma was screened from healthy donors to treat OSCC cells and to prepare for anti-HER2 intravenous immunoglobulin (IVIg). Both anti-HER2 IgG-abundant plasma and anti-HER2 IVIg could significantly inhibit proliferation and invasion of OSCC cells by inducing the apoptosis, and also regulate apoptosis-associated factors and epithelial-mesenchymal transition (EMT), respectively. Besides, the complement-dependent cytotoxicity (CDC) pathway was likely to contribute to the anti-HER2 IgG mediated inhibition of OSCC cells. After the HER2 gene was knocked down with HER2-specific siRNAs, the inhibitory effects on OSCC cell proliferation and apoptotic induction faded away. In conclusion, human plasma IgG, or IVIg against HER2 may be a promising agent for anti-OSCC therapy.

show abstract

Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies

Cited by 89 publications

References 94 publications

An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH

An antibody Fc engineered for conditional antibody-dependent cellular cytotoxicity at the low tumor microenvironment pH

Cancer Immunotherapies: What the Perioperative Physician Needs to Know

Circulating Natural Autoantibodies to HER2-Derived Peptides Performed Antitumor Effects on Oral Squamous Cell Carcinoma

Contact Info

Product

Resources

About